ZYC 200

Drug Profile

ZYC 200

Alternative Names: ZYC200

Latest Information Update: 12 Mar 2008

Price : $50

At a glance

  • Originator MGI Pharma Biologics
  • Class Anti-inflammatories
  • Mechanism of Action Immunosuppressants; Melanocyte stimulating hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 08 Dec 2003 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
  • 08 Dec 2003 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
  • 08 Dec 2003 No development reported - Preclinical for Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top